TY - JOUR
T1 - A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
AU - Bartlett, Nancy L.
AU - Herrera, Alex F.
AU - Domingo-Domenech, Eva
AU - Mehta, Amitkumar
AU - Forero-Torres, Andres
AU - Garcia-Sanz, Ramon
AU - Armand, Philippe
AU - Devata, Sumana
AU - Izquierdo, Antonia Rodriguez
AU - Lossos, Izidore S.
AU - Reeder, Craig
AU - Sher, Taimur
AU - Chen, Robert
AU - Schwarz, Sylvia E.
AU - Alland, Leila
AU - Strassz, Andras
AU - Prier, Kim
AU - Choe-Juliak, Cassandra
AU - Ansell, Stephen M.
N1 - Funding Information:
This study was supported by Affimed GmbH.
Funding Information:
Conflict-of-interest disclosure: N.L.B. reports grant funding from Affimed, BMS, and Merck; A.F.H. reports grant funding from AstraZeneca, BMS, Gilead, Immune Design, KiTe Pharma, Merck, and Seattle Genetics, and personal fees from Adaptive Biotechnologies, BMS, Genentech, KiTe Pharma, Merck, and Seattle Genetics; E.D.-D. reports personal fees from BMS and Takeda and nonfinancial support from Roche and Takeda; S.M.A. reports grant funding from Affimed, AI Therapeutics, BMS, Regeneron, Seattle Genetics, and Trillium; A.M. reports grant funding from Affimed, ADC Therapeutics, ASTEX, BMS, Celgene, FortySeven Inc., Gilead, Incyte, KiTe Pharma, Juno, Merck, Oncotartis, Pharmacy-clics, Rhizen, Roche-Genentech, Seattle Genetics, and Takeda, and personal fees from AstraZeneca, BMS, Celgene, Gilead, KiTe Pharma, Juno, Pharmacyclics, and Seattle Genetics; A.F.-T. reports grant funding by UAB and is a former employee of Seattle Genetics; R.G.-S. reports clinical grant funding from Takeda and University Hospital of Salamanca, CME fees from the Spanish Society of Hematology, personal fees from Beyond Spring, Janssen-Cilag, Roche, and Takeda, and grant funding from Gilead; P.A. reports consultancy services from Affimed, Adaptive, ADC Therapeutics, BMS, Celgene, Merck, Morphosys, and Pfizer, grant funding from Affimed, Adaptive, BMS, Genentech, IGM, Merck, Otsuka, Tensha, and Sigma t, and personal fees from BMS and Merck; and S.E.S., L.A., A.S., K.P., and C.C.-J. are employees of Affimed. The remaining authors declare no competing financial interests.
PY - 2020/11/19
Y1 - 2020/11/19
N2 - In relapsed/refractory Hodgkin lymphoma (R/R HL), immunotherapies such as the anti-programmed death-1 inhibitor pembrolizumab have demonstrated efficacy as monotherapy and are playing an increasingly prominent role in treatment. The CD30/CD16A-bispecific antibody AFM13 is an innate immune cell engager, a first-in-class, tetravalent antibody, designed to create a bridge between CD30 on HL cells and the CD16A receptor on natural killer cells and macrophages, to induce tumor cell killing. Early studies of AFM13 have demonstrated signs of efficacy as monotherapy for patients with R/R HL and the combination of AFM13 with pembrolizumab represents a rational new treatment modality. Here, we describe a phase 1b, dose-escalation study to assess the safety and preliminary efficacy of AFM13 in combination with pembrolizumab in patients with R/R HL. The primary objective was estimating the maximum tolerated dose; the secondary objectives were to assess safety, tolerability, antitumor efficacy, pharmacokinetics, and pharmacodynamics. In this heavily pretreated patient population, treatment with the combination of AFM13 and pembrolizumab was generally well tolerated, with similar safety profiles compared to the known profiles of each agent alone. The combination of AFM13 with pembrolizumab demonstrated an objective response rate of 88% at the highest treatment dose, with an 83% overall response rate for the overall population. Pharmacokinetic assessment of AFM13 in the combination setting revealed a half-life of up to 20.6 hours. This proof-of-concept study holds promise as a novel immunotherapy combination worthy of further investigation. This phase 1b study was registered at www.clinicaltrials.gov as NCT02665650.
AB - In relapsed/refractory Hodgkin lymphoma (R/R HL), immunotherapies such as the anti-programmed death-1 inhibitor pembrolizumab have demonstrated efficacy as monotherapy and are playing an increasingly prominent role in treatment. The CD30/CD16A-bispecific antibody AFM13 is an innate immune cell engager, a first-in-class, tetravalent antibody, designed to create a bridge between CD30 on HL cells and the CD16A receptor on natural killer cells and macrophages, to induce tumor cell killing. Early studies of AFM13 have demonstrated signs of efficacy as monotherapy for patients with R/R HL and the combination of AFM13 with pembrolizumab represents a rational new treatment modality. Here, we describe a phase 1b, dose-escalation study to assess the safety and preliminary efficacy of AFM13 in combination with pembrolizumab in patients with R/R HL. The primary objective was estimating the maximum tolerated dose; the secondary objectives were to assess safety, tolerability, antitumor efficacy, pharmacokinetics, and pharmacodynamics. In this heavily pretreated patient population, treatment with the combination of AFM13 and pembrolizumab was generally well tolerated, with similar safety profiles compared to the known profiles of each agent alone. The combination of AFM13 with pembrolizumab demonstrated an objective response rate of 88% at the highest treatment dose, with an 83% overall response rate for the overall population. Pharmacokinetic assessment of AFM13 in the combination setting revealed a half-life of up to 20.6 hours. This proof-of-concept study holds promise as a novel immunotherapy combination worthy of further investigation. This phase 1b study was registered at www.clinicaltrials.gov as NCT02665650.
UR - http://www.scopus.com/inward/record.url?scp=85094889706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094889706&partnerID=8YFLogxK
U2 - 10.1182/BLOOD.2019004701
DO - 10.1182/BLOOD.2019004701
M3 - Article
C2 - 32730586
AN - SCOPUS:85094889706
VL - 136
SP - 2401
EP - 2409
JO - Blood
JF - Blood
SN - 0006-4971
IS - 21
ER -